TY - JOUR
T1 - Nerve growth factor and autophagy
T2 - Effect of nasal anti-NGF-antibodies administration on Ambra1 and Beclin-1 expression in rat brain
AU - Rosso, Pamela
AU - Moreno, Sandra
AU - Fracassi, Anna
AU - Rocco, Maria Luisa
AU - Aloe, Luigi
N1 - Publisher Copyright:
© 2015 Taylor & Francis.
PY - 2015/9/3
Y1 - 2015/9/3
N2 - Nerve growth factor (NGF) exerts protective actions in the healthy and diseased nervous system. Intranasal administration is a suitable and safe strategy to deliver NGF to CNS neurons. We investigated whether nasal anti-NGF-antibody (ANA) administration affects neuronal autophagy, in view of its putative regulatory role in this process. We focused on olfactory bulbs (OB), neocortex (Cx), hippocampus (HF) and septal complex (SC), known to be NGF-responsive and autophagically active. Our combined molecular/morphological results demonstrate that intranasally administered ANA reaches brain NGF-target neurons and lowers the levels of endogenous NGF and its receptors. Treatment also affects - in a brain region-dependent manner - the expression of the autophagic proteins Beclin-1 and Ambra1, as well as that of proteins belonging to the Bcl2 family, namely Bax and Bcl-2, reflecting apoptotic dysregulation. This study provides a nongenetically modified, NGF-defective animal model, representing a suitable tool to investigate novel properties of the neurotrophin, especially in relation to autophagy.
AB - Nerve growth factor (NGF) exerts protective actions in the healthy and diseased nervous system. Intranasal administration is a suitable and safe strategy to deliver NGF to CNS neurons. We investigated whether nasal anti-NGF-antibody (ANA) administration affects neuronal autophagy, in view of its putative regulatory role in this process. We focused on olfactory bulbs (OB), neocortex (Cx), hippocampus (HF) and septal complex (SC), known to be NGF-responsive and autophagically active. Our combined molecular/morphological results demonstrate that intranasally administered ANA reaches brain NGF-target neurons and lowers the levels of endogenous NGF and its receptors. Treatment also affects - in a brain region-dependent manner - the expression of the autophagic proteins Beclin-1 and Ambra1, as well as that of proteins belonging to the Bcl2 family, namely Bax and Bcl-2, reflecting apoptotic dysregulation. This study provides a nongenetically modified, NGF-defective animal model, representing a suitable tool to investigate novel properties of the neurotrophin, especially in relation to autophagy.
KW - Ambra1
KW - Anti-NGF-antibodies (ANA)
KW - Autophagy
KW - Beclin-1
KW - Nasal administration
KW - Nerve growth factor (NGF)
UR - http://www.scopus.com/inward/record.url?scp=84955195280&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955195280&partnerID=8YFLogxK
U2 - 10.3109/08977194.2015.1122002
DO - 10.3109/08977194.2015.1122002
M3 - Article
C2 - 26728403
AN - SCOPUS:84955195280
SN - 0897-7194
VL - 33
SP - 401
EP - 409
JO - Growth Factors
JF - Growth Factors
IS - 5-6
ER -